Screener
Innospec IOSP R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Innospec in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Innospec’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 9:34 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213510
| (in millions, except share and per share data) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Gross profit | 123.5 | 125.1 |
| Operating expenses: | ||
| Selling, general and administrative | (78.5) | (69.3) |
| Research and development | (13.2) | (12.7) |
| Adjustment to fair value of contingent consideration | 4.7 | (0.7) |
| Profit on disposal of property, plant and equipment | — | 0.1 |
| Total operating expenses | (87.0) | (82.6) |
| Operating income | 36.5 | 42.5 |
Item 1 Condensed Consolidated Financial Statements
FAQ
- What is Innospec's R&D?
- Innospec (IOSP) reported R&D of $13.2M in Q1 2026.
- How has Innospec's R&D changed year-over-year?
- Innospec's R&D increased by 3.9% year-over-year, from $12.7M to $13.2M.
- What is the long-term trend for Innospec's R&D?
- Over 4 years (2021 to 2025), Innospec's R&D has grown at a 8.1% compound annual growth rate (CAGR), from $37.4M to $51M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Innospec's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude